Zenas Biopharma's Purchased 60,000: Insider Buy Deep Dive
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Which Investors Should Avoid Robo Advisors outlines situations where automated options may underperform. This intro highlights alternatives to consider.
28,175 articlesA biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
Raymond James raises Marathon's target to 270, driven by sustained refining margins and strong MPLX distributions. MP...
This analysis dives into the early 2026 earnings picture for J.Jill, unpacking revenue drivers, margin dynamics, and ...
Circle helped popularize stablecoins with USDC, but looming regulatory moves could reshape its growth path. This arti...
Coca-Cola has staged a remarkable rally this year, outpacing the broader market. Yet many investors wonder if this ri...
If you’ve never invested passively, the idea of evaluating a syndicator can feel intimidating. This guide breaks down...
A small AI-focused player claims it helps customers turn modest marketing spend into impressive gains. This piece bre...
A close look at tapestry (tpr) 2026 earnings reveals what drives revenue, margins, and stock performance. Learn how t...
ServiceNow faced real headwinds long before the AI hype. This article breaks down the root causes, their impact on ma...
As CI&T launches into 2026, investors are scanning for momentum, margin resilience, and strategic bets. This deep div...
Figma trades higher ahead of tonight’s Q1 print, as analysts eye revenue growth and AI momentum. Live coverage tracks...
Lionsgate faces a pivotal year as it balances streaming momentum with theatrical cycles and debt. This guide breaks d...